N-methyl-D-aspartate receptor glutamate binding site (NMDAR glutamate site)

The N-methyl-D-aspartate (NMDA) receptor is a heterotetrameric ionotropic glutamate receptor that plays a fundamental role in excitatory neurotransmission and synaptic plasticity within the central nervous system [1.2.1, 1.2.3]. It is uniquely characterized by its requirement for the simultaneous binding of two agonists: L-glutamate at the glutamate site, located on the GluN2 subunits, and glycine or D-serine at the glycine site, located on the GluN1 subunits [1.3.1, 1.4.1]. The glutamate binding site is the primary orthosteric site for the endogenous neurotransmitter, and its activation, coupled with postsynaptic depolarization to remove the magnesium block, allows for the influx of calcium ions [1.3.1, 1.4.3]. This calcium signaling is essential for processes such as long-term potentiation (LTP) and long-term depression (LTD), which serve as the cellular basis for learning and memory [1.2.2, 1.2.4]. Dysregulation of the NMDA receptor, particularly through overactivation leading to excitotoxicity or chronic hypofunction, is implicated in a wide range of neurological and psychiatric conditions, including Alzheimer's disease, schizophrenia, and stroke [1.1.2, 1.2.3]. While many drugs target the NMDA receptor, those specifically interacting with the glutamate site are typically competitive antagonists; many of these have been explored for neuroprotection but have faced significant challenges in clinical development due to adverse effects such as dissociation and cognitive impairment [1.2.3, 1.4.1].

Other names

GluN2 glutamate binding siteNMDA receptor orthosteric siteL-glutamate binding site of the NMDA receptorNMDAR glutamate siteNR2 glutamate binding site

Competitive antagonism of the glutamate binding site on the GluN2 subunits of the NMDA receptor, preventing activation by endogenous L-glutamate, or orthosteric agonism to stimulate receptor activity.